Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several core label elements are supported (indication, active ingredient, mechanism concept, administration by healthcare professionals, monitoring/lab monitoring, and hepatic/hemorrhage/blood-count related concerns). However, some claims are not explicitly supported as written (e.g., wording about asparagine dependence, and that ALL “need asparaginase therapy” within protocols), and at least one safety/administration detail is generalized beyond the provided label excerpts.
Category Scores
Accurate Statements
Asparlas is a medicine used for acute lymphoblastic leukemia (ALL).
1 INDICATIONS AND USAGE: “ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.”
Asparlas contains the enzyme asparaginase.
11 DESCRIPTION: “Each vial of ASPARLAS contains 3,750 units… Each milliliter contains 750 units of calaspargase pegol-mknl…” and 12.1 Mechanism: “catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia...” (calaspargase pegol-mknl is an asparaginase conjugate).
Asparaginase breaks down asparagine in the body.
12.1 Mechanism of Action: “catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia...” and “depletion of plasma asparagine.”
Asparlas is administered by healthcare professionals.
2 DOSAGE AND ADMINISTRATION: “ASPARLAS is administered by IV infusion” and 2.4 Preparation and Administration refers to administration/discarding/inspection prior to administration (indicates administration in clinical setting by healthcare staff).
The exact administration details depend on the treatment plan and the product’s prescribed regimen.
2 DOSAGE AND ADMINISTRATION and 1 INDICATIONS: indicated “as a component of a multi-agent chemotherapeutic regimen” (supports regimen dependence).
Monitoring is part of standard use of asparaginase products.
2.3 Recommended Monitoring and Dosage Modifications: “Monitor patients at least weekly with bilirubin, transaminases, glucose, and clinical examinations…” and 5 WARNINGS/ PRECAUTIONS: hepatotoxicity monitoring including bilirubin/transaminases and frequent monitoring for hepatic VOD.
Typical safety concerns with asparase therapies include effects on liver function.
5.5 Hepatotoxicity, Including Hepatic Veno-Occlusive Disease: “Evaluate bilirubin and transaminases prior to each dose… and at least weekly… through 6 weeks… Monitor frequently for signs and symptoms of hepatic VOD…”
Typical safety concerns with asparase therapies include changes in blood clotting.
5.4 Hemorrhage: “Evaluate patients… with coagulation parameters including PT, PTT, fibrinogen.”
Typical safety concerns with asparase therapies include changes in blood counts.
2.3 and 5.4 Hemorrhage relate to clinical/coagulation parameters; however provided excerpts also support clinical examinations and “throughout recovery,” which are monitoring elements. (No explicit phrase “blood counts” in provided excerpts; see unsupported statement for mismatch.)
Prescribing details for Asparlas, including indications, dosing schedules, and safety monitoring, are provided in the official product information.
Label structure provided includes Indications (1), Dosage and Administration (2), and Warnings/Precautions and Monitoring (5/2.3).
Unsupported Statements
Many ALL cells depend on asparagine to survive.
12.1 describes mechanism as “killing of leukemic cells due to depletion of plasma asparagine” but the statement that “many ALL cells depend on asparagine to survive” is not explicitly stated in the provided excerpts.
Reducing asparagine helps kill cancer cells in acute lymphoblastic leukemia.
12.1 supports that pharmacological effect is “thought to be based on the killing of leukemic cells due to depletion of plasma asparagine,” but the claim is slightly broader and specific to “acute lymphoblastic leukemia” as a direct causal effect; the provided excerpt ties to leukemic cells generally without explicitly stating this phrasing.
Asparlas is used in acute lymphoblastic leukemia, including cases where asparaginase therapy is needed as part of chemotherapy protocols.
The label supports use “as a component of a multi-agent chemotherapeutic regimen,” but the specific phrasing “including cases where asparaginase therapy is needed as part of chemotherapy protocols” is not explicitly stated in the provided excerpts.
Typical safety concerns with asparase therapies include changes in blood counts.
Provided excerpts explicitly mention monitoring bilirubin, transaminases, glucose, clinical examinations, coagulation parameters (PT/PTT/fibrinogen), and hepatic VOD; they do not explicitly mention “blood counts” in the supplied text.
Asparaginase products can cause serious side effects.
The label excerpt describes serious adverse reactions (e.g., hypersensitivity including anaphylaxis, pancreatitis, thrombosis, hemorrhage, hepatotoxicity including VOD), but the generalized statement “can cause serious side effects” is not directly phrased in the provided excerpts.
Monitoring is part of standard use of asparaginase products.
The provided excerpt supports monitoring for ASPARLAS specifically (2.3 and 5.5), but the wording “asparase products” (general class) is broader than the label excerpt focus on ASPARLAS.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
No dosing details were provided (e.g., “2,500 units/m^2 given intravenously no more frequently than every 21 days”), despite the claim being about administration and safety in general.
Importance:
Moderate
No mention of required premedication regimen (acetaminophen, H-1 blocker such as diphenhydramine, and H-2 blocker such as famotidine 30–60 minutes prior).
Importance:
Moderate
No contraindications were addressed (e.g., severe hepatic impairment; serious hypersensitivity; pancreatitis; thrombosis; hemorrhagic events during prior L-asparaginase therapy).
Importance:
Moderate
Monitoring frequency/window details for hepatotoxicity (e.g., at least weekly through 6 weeks after last dose) were not specified.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Potential risk from generalized/partially unsupported statements and omissions of key label specifics (premedication, exact dosing interval, and contraindications).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims are generalized or not explicitly supported by the provided label excerpts (especially the asparagine-dependence statement, class-general “asparase products,” and “blood counts” wording), and key label specifics (dose, premedication, contraindications) are omitted.
Suggested Improvement
Restrict phrasing to label-supported statements (e.g., use label language about depletion of plasma asparagine and leukemic cell killing), specify ASPARLAS dosing interval (2,500 units/m^2 IV no more frequently than every 21 days), include label premedication and contraindications, and replace “blood counts” with explicitly supported parameters (bilirubin/transaminases/glucose/clinical exam; coagulation parameters PT/PTT/fibrinogen).